Key result
SGLT2 inhibitor exposure after TAVR in patients with diabetes was associated with lower risks of major adverse cardiovascular events, cardiovascular mortality, heart failure exacerbation, and stroke.
Why the study?
Does SGLT2i use lower the risk of cardiovascular and renal events in patients with diabetes after TAVR?
Does SGLT2i use lower the risk of cardiovascular and renal events in patients with diabetes after TAVR?
Observational data suggests SGLT2 inhibitors may reduce cardiovascular and renal events when used in diabetic patients after TAVR.
We read with interest the study by Hanif et al evaluating sodium-glucose cotransporter-2 inhibitor (SGLT2i) use after transcatheter aortic valve replacement (TAVR) in patients with diabetes.1 In a large multinational electronic health record cohort, SGLT2i exposure was associated with lower risks of major adverse cardiovascular events, cardiovascular mortality, heart failure (HF) exacerbation, stroke, and renal events. These findings are clinically relevant and complement emerging randomized evidence supporting SGLT2 inhibition after TAVR.
No takes yet. Share an insight, caveat, or question.
Tareen et al. (2026) conducted a letter in Diabetes after transcatheter aortic valve replacement (TAVR). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) was evaluated on Major adverse cardiovascular events, cardiovascular mortality, heart failure exacerbation, stroke, and renal events. SGLT2 inhibitor exposure after TAVR in patients with diabetes was associated with lower risks of major adverse cardiovascular events, cardiovascular mortality, heart failure exacerbation, and stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: